Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

HCA Healthcare, Inc.

HCACIK 0000860730Healthcare

Compare:LH WST BAX MCK CI UNH

Compare HCA

Intrinsic Value

HCA Intrinsic Valuation

Review the filing-backed discounted cash flow baseline, scenario range, and capital structure context for a fundamentals-first fair value read.

Intrinsic Value

HCA Intrinsic Valuation

Review the filing-backed discounted cash flow baseline, scenario range, and capital structure context for a fundamentals-first fair value read.

Intrinsic value

Filing-backed DCF baseline

Automated free-cash-flow DCF baseline for HCA Healthcare, Inc., derived from annual filing data.

Read the DCF guide

DCF fair value

$187.37

Implied equity value $45B

Current price

—

Latest available quote for the primary listing.

Margin of safety

N/A

Live market price unavailable. Refreshing the route will retry the quote.

Fair value range

$130.81 – $261.03

Bear

$130.81

Base

$187.37

Bull

$261.03

Model assumptions

Cash flow base

$6B

Basis

Operating cash flow less capex (firm-value proxy)

Growth

7.9%

Discount

10.5%

Terminal

2.5%

Horizon

Assumption sensitivity

vs base per share

Base case$187.37Baseline

Growth +1 pt$245.77+$58.40

Intrinsic value

Filing-backed DCF baseline

Automated free-cash-flow DCF baseline for HCA Healthcare, Inc., derived from annual filing data.

Read the DCF guide

DCF fair value

$187.37

Implied equity value $45B

Current price

—

Latest available quote for the primary listing.

Margin of safety

N/A

Live market price unavailable. Refreshing the route will retry the quote.

Fair value range

$130.81 – $261.03

Bear

$130.81

Base

$187.37

Bull

$261.03

Model assumptions

Cash flow base

$6B

Basis

Operating cash flow less capex (firm-value proxy)

Growth

7.9%

Discount

10.5%

Terminal

2.5%

Horizon

Assumption sensitivity

vs base per share

Base case$187.37Baseline

Growth +1 pt$245.77+$58.40

What the market is pricing in

Market expectations cannot be backed out until price, share count, cash-flow base, discount rate, terminal growth, and the EV-to-equity bridge are all available.
Growth anchor: Median of 3Y revenue CAGR, 5Y revenue CAGR, and 5Y free cash flow CAGR. Scenario-derived from +/-2 pts growth and +/-1 pt discount.
Net debt reduces equity value relative to firm value before the per-share target is calculated.

Intrinsic EV-to-equity bridge

Enterprise value

Discounted free cash flows

$90B

Less total debt

− $46B

Plus cash and equivalents

+ $1B

Equity value

After the bridge

$45B

Diluted shares

239,495,000

Fair value / share

$187.37